Abstract
Depression is a severe mental disorder among public health issues. Researchers in the field of mental health and clinical psychiatrists have long been faced with difficulties in slow treatment cycles, high recurrence rates, and lagging efficacy. These obstacles have forced us to seek more advanced and effective treatments. Research has shown that novel drug delivery strategies for natural medicinal plants can effectively improve the utilization efficiency of the active molecules in these plants and therefore improve their efficacy. Currently, with the development of treatment technologies and the constant updating of novel drug delivery strategies, the addition of natural medicinal antidepressant therapy has given new significance to the study of depression treatment against the background of novel drug delivery systems. Based on this, this review comprehensively evaluates and analyses the research progress in novel drug delivery systems, including nanodrug delivery technology, in intervention research strategies for neurological diseases from the perspective of natural medicines for depression treatment. This provided a new theoretical foundation for the development and application of novel drug delivery strategies and drug delivery technologies in basic and clinical drug research fields.
Graphical Abstract
![](http://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12951-023-02159-9/MediaObjects/12951_2023_2159_Figa_HTML.png)
Similar content being viewed by others
Introduction
Depression is a widespread and potentially life-threatening neurological disorder that has garnered attention from researchers around the world. It not only has psychological manifestations involving emotions and cognition but also manifests neurological damage, such as decreased volition and cognitive impairment, and even physical symptoms, such as autonomic nervous system dysfunction. Moreover, depression often co-occurs with other psychiatric disorders, such as posttraumatic stress disorder, anxiety disorders, obsessive–compulsive disorder, and substance use disorders, and comorbidities, such as cardiovascular disease, diabetes, stroke, and cancer, frequently occur [1]. Depression has become a highly concerning public health issue on an international scale. However, due to the complex pathological mechanisms of neurological diseases, frontline health care professionals often face clinical difficulties such as complex adverse reactions and low treatment efficacy. As a result, scientists have started contemplating multiple possible treatment strategies. The combination of natural medicines and novel drug delivery systems (NDDSs) has entered our vision.
The attributes of natural medicines, possessing mechanisms of action that can intervene in multiple disease targets and pathways, have stimulated considerable interest among researchers in natural drug antidepressant therapies. Natural medications have the characteristics of fewer adverse reactions, significant therapeutic effects, and the ability to function in synergy with multiple components. Compared to traditional synthesized small-molecule drugs, natural drugs also have the advantages of abundant resources, low cost, and easy availability, making them an important source of new drug development. More than half of the new chemical entity drugs developed internationally are directly or indirectly derived from natural medications. Natural medications have enormous medical value and market potential.
The vigorous development of science and technology has brought breakthroughs in medical technology. The updating of the research content and paradigm in the field of drug delivery systems has solved multiple problems in drug bioavailability and stability, providing more possibilities for the treatment of clinical nervous system disorders. The breakthroughs in drug delivery routes and delivery vehicle research in the drug delivery system field have improved the efficacy of drugs used to treat nervous system diseases. The emergence of NDDSs has shown new clinical prospects in the formulation research of drugs. The development and maturity of drug delivery technology have provided impetus for the clinical transformation of many new drugs.
With the development of pharmaceuticals and the high pursuit of efficacy, the medical community has conducted further development and research on the enhancement of the absorption efficiency of active ingredients in natural medicines through the application of NDDS technology, which has resulted in notable therapeutic outcomes. Mature scientific research methods, such as nanotechnology, have significantly propelled the development of natural medicinal plant antidepressant treatment practices. Therefore, this review discusses interventions in neurological disease research from the perspective of novel drug delivery systems and involves exploring natural medicinal plant antidepressant strategies. The information in this review provides a novel theoretical foundation for studying new delivery strategies of natural medicinal plant active ingredients in the field of psychiatric research.
Obstacles to traditional drug delivery methods and obstacles to BBB
Based on the evidence from modern medical systems, natural medicines encompass plant-, animal-, and mineral-derived drugs that possess pharmacological effects. Among these, plant-based medicines predominate in natural medicine, whereas animal, mineral, and other forms of natural medicines are used to a relatively lesser extent. Over time, various applied systematic theories have evolved in the field of natural medicine, including Chinese medicine, Indian Buddhist medicine, Islamic medicine, European traditional herbal medicine, South American ethnomedicine, and African ethnomedicine.
The study of nervous system diseases in traditional Chinese medicine (TCM) has a long history; as early as the Shang and Zhou Dynasties in ancient China, there were records about brain disorders in oracle bone inscriptions, such as ‘King Wu was diagnosed due to headaches’ [2]. ‘Huang Di Nei **’ also contains numerous discussions on brain disorders [3, 158]. The intranasal administration of Panax ginseng saponin was found to significantly alleviate cerebral oedema and stroke symptoms resulting from cerebral ischaemia‒reperfusion in gerbils, while administering the same dose of an oral solution had minimal effect [159].
Ototopical administration
The 'Inner Canon of the Yellow Emperor' (the most authoritative text of early medical theory and drug therapy), a classical text on Chinese medicine, associates the ear with the brain and suggests that damage to the brain can result in damage to the ear [160]. Furthermore, the Chinese medical text ‘Suwen-Xuanji-original disease Formula’ contains records of acupuncture and magnetic therapy being used to treat deafness. The traditional Chinese medicine approach to treating ear issues is a distinct and specialized technique within this field [161]. Based on Chinese medicine principles, the ear is interconnected with internal organs and meridians. Consequently, when medication is administered via the external ear canal, it can travel through the meridian and access the internal organs, successfully treating illnesses and even saving lives [162, 203]. The blood‒brain barrier is a highly specialized structure that limits the movement of compounds between the blood and brain tissue. This barrier is created by a unique arrangement of components, including the nonporous endothelium of the brain capillaries, a continuous and unbroken basement membrane, and the perivascular astrocytic foot processes. These components possess varied permeability to different substances, which contributes to the selective transport of molecules into the brain [].
Modulating BBB permeability is a microenvironmental modification strategy aimed at selectively enhancing or restricting the passage of substances. The permeability of the blood‒brain barrier is primarily dictated by the integrity of the tight junctions between cerebral vascular endothelial cells, as well as the activity of efflux transporters such as P-glycoprotein (P-gp). Other factors, such as intercellular gaps, endocytosis, and transcytosis, also play a role in regulating BBB permeability [204]. Due to their fat solubility and aromatic properties, certain Kaigiao herbs, such as musk, borneol, and Acorus calamus, are able to readily cross the blood‒brain barrier. These herbs have been shown to inhibit the efflux of P-gp, resulting in increased drug concentrations within the brain. Additionally, these herbs have been found to suppress the expression of the protein Claudin-5, which widens the tight junctions between vascular endothelial cells, thereby enhancing BBB permeability. Acorus tatarinowii and borneol also increase the content of 5-hydroxy tryptamine (5-HT) and receptor binding rates, promoting the opening of tight junctions via endothelial cell contraction and increasing BBB permeability. Furthermore, Storesin and benzoin have been shown to increase BBB permeability by modulating P-gp exocytosis [168, 205]. Under pathological conditions, musk, borneol, Storesin, and benzoin have been found to reduce the content of inflammatory factors, which slows the damage of tight junctions between endothelial cells. Musk has also been shown to inhibit matrix metalloproteinase expression and mitigate cell damage caused by free radicals, promoting increased stability and reducing the permeability of the BBB and protecting brain tissues. Acorus calamus is capable of reducing BBB permeability through its anti-free radical properties, protecting brain tissues [206]. Cai Wei**’s study explored the effects of sodium hesperidin on the sarcoma homologue A (RhoA)/Rho-associated coiled-coil protein kinase (ROCK) pathway and BBB permeability in rats with bacterial meningitis (BM). The study demonstrated that sodium aescinate (SA) was able to improve brain oedema and BBB permeability in rats with BM. These beneficial effects of SA on BBB damage may be attributed to the inhibition of Rohan/ROCK pathway activation [207].
Concluding remarks and future perspective
In recent years, there has been a gradual increase in the incidence of depression. However, due to the unique structural characteristics of the BBB in neurological disorders, active drug molecules are unable to accumulate in brain lesions, severely impacting the effectiveness of treatment. Therefore, the search for novel and efficient drugs to treat brain diseases has become an urgent matter in today’s society. Domestic and international research has demonstrated that certain new drug delivery systems are capable of partially overcoming the BBB limitations and delivering drugs to focal areas in the brain, thus improving therapeutic effectiveness. The research and development of new systems have become a focus of clinical development. The aim of novel drug delivery systems, such as nanomedicines, liposomes, microneedles, and subcutaneous injections, is to improve drug efficacy and reduce side effects while enhancing patient compliance. These systems have advantages in terms of drug delivery, enhanced drug efficacy, controlled drug release, and other aspects and have achieved certain results in clinical development (Table 5).
NDDSs are the foundation of drug formulation research and play a pivotal role in the development of the global pharmaceutical industry. The focus of NDDS research is to optimize drug efficacy and reduce unwanted side effects by implementing three fundamental strategies: targeting space, release time, and dose. The scope of NDDSs encompasses various objectives, such as controlled drug release, drug targeting, enhanced drug stability, the regulation of drug metabolism time, improved drug absorption, and overcoming biological barriers.
The cornerstone of modernizing Chinese medicine lies in the modernization of Chinese medicine formulations. By harnessing the advantages of traditional Chinese medicine in treating brain diseases and integrating modern new drug delivery systems, Chinese medicine can effectively treat brain diseases and the dosage forms of Chinese medicines can be improved. The key factors affecting the ability of a drug to cross the BBB include its lipid solubility, molecular weight, and dissociated or nondissociated form under physiological conditions. NDDSs have demonstrated the ability to enhance the ability of Chinese medicines to penetrate the BBB and increase drug concentrations in the brain. This combination of strengths minimizes the adverse effects of Chinese medicines while maximizing their therapeutic benefits.
In conclusion, the vast potential of Chinese medicine remains largely untapped. Outdated drug delivery methods have limited the efficacy of Chinese medicines. The application of new drug delivery technologies to Chinese herbal medicines will undoubtedly help to enhance the therapeutic efficacy of various Chinese medicinal compounds and herbs while reducing the side effects of drugs. The progress made by modern science has provided additional opportunities to explore the benefits of Chinese medicine. While new drug delivery systems have shown promise in treating brain diseases, they are still in their early stages, and numerous challenges are encountered. Further research is necessary to refine drug delivery carriers and optimize TCM formulations.
Availability of data and materials
The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.
Abbreviations
- ADA:
-
Adenosine deaminase
- ADV:
-
Adenoviruses
- ADA-SCID:
-
Adenosine deaminase Severe combined immune deficiency
- API:
-
Active pharmaceutical ingredient
- 5-ASA:
-
5-Amino Salicylic Acid
- BBB:
-
Blood brain barrier
- BCECs:
-
Brain capillary endothelial cells
- BM:
-
Bacterial meningitis
- Chronic CSDS:
-
Social defeat stress depression
- DDS:
-
Drug delivery systems
- D2:
-
Dopamine2
- EMA:
-
European Medicines Agency
- EGFR:
-
Epidermal growth factor receptor
- Gen:
-
Genistein
- LV:
-
Lentiviruses
- MGB:
-
Microbe-gut-brain
- MAO:
-
Monoamine oxidase
- mAbs:
-
Monoclonal antibodies
- NSCLC:
-
Non-small cell lung cancer
- NDDS:
-
Novel drug delivery systems
- PK:
-
Pharmacokinetic
- PEG-PLGA:
-
Polyethylene glycol-poly lactic acid-hydroxyacetic acid
- PLGA:
-
Poly lactic-co-glycolic acid
- P-gp:
-
P-glycoprotein
- ROCK:
-
Rho-associated coiled-coil protein kinase
- RV:
-
Retroviruses
- SLNs:
-
Solid lipid nanoparticles
- SA:
-
Sodium aescinate
- SARS-CoV-2:
-
Severe Acute Respiratory Syndrome Coronavirus 2
- TCM:
-
Traditional Chinese Medicine
- TEER:
-
Transendothelial resistance
References
Smith K. Mental health: a world of depression. Nature. 2014;515:180–181.
Feng ST, Wang XL, Wang YT, Yuan YH, Li ZP, Chen NH, Wang ZZ, Zhang Y. Efficacy of Traditional chinese medicine combined with selective serotonin reuptake inhibitors on the treatment for Parkinson’s disease with depression: a systematic review and meta-analysis. Am J Chin Med. 2021;49:627–643.
Zhang Y, Wang ZZ, Sun HM, Li P, Li YF, Chen NH. Systematic review of traditional chinese medicine for depression in Parkinson’s disease. Am J Chin Med. 2014;42:1035–1051.
Zhang G, **ong N, Zhang Z, Liu L, Huang J, Yang J, Wu J, Lin Z, Wang T. Effectiveness of traditional Chinese medicine as an adjunct therapy for Parkinson’s disease: a systematic review and meta-analysis. PLoS ONE. 2015;10: e0118498.
Cheng G, Liu Y, Ma R, Cheng G, Guan Y, Chen X, Wu Z, Chen T. Anti-Parkinsonian therapy: strategies for crossing the blood-brain barrier and nano-biological effects of nanomaterials. Nanomicro Lett. 2022;14:105–109.
Gao H. Progress and perspectives on targeting nanoparticles for brain drug delivery. Acta Pharm Sin B. 2016;6:268–286.
Daneman R, Prat A. The blood-brain barrier. Cold Spring Harb Perspect Biol. 2015;7: a020412.
Reeve A, Simcox E, Turnbull D. Ageing and Parkinson’s disease: why is advancing age the biggest risk factor? Ageing Res Rev. 2014;14:19–30.
Neuwelt E, Abbott NJ, Abrey L, Banks WA, Blakley B, Davis T, Engelhardt B, Grammas P, Nedergaard M, Nutt J, et al. Strategies to advance translational research into brain barriers. Lancet Neurol. 2008;7:84–96.
Nagpal K, Singh SK, Mishra DN. Drug targeting to brain: a systematic approach to study the factors, parameters and approaches for prediction of permeability of drugs across BBB. Expert Opin Drug Deliv. 2013;10:927–955.
Pardridge WM. Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv. 2003;3(90–105):151–156.
Chen Y, Liu L. Modern methods for delivery of drugs across the blood-brain barrier. Adv Drug Deliv Rev. 2012;64:640–665.
Takata F, Nakagawa S, Matsumoto J, Dohgu S. Blood-brain barrier dysfunction amplifies the development of neuroinflammation: understanding of cellular events in brain microvascular endothelial cells for prevention and treatment of BBB dysfunction. Front Cell Neurosci. 2021;15: 661838.
Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008;57:178–201.
Daneman R. The blood-brain barrier in health and disease. Ann Neurol. 2012;72:648–672.
Profaci CP, Munji RN, Pulido RS, Daneman R. The blood-brain barrier in health and disease: important unanswered questions. J Exp Med. 2020;217: e20190062.
Tosi G, Duskey JT, Kreuter J. Nanoparticles as carriers for drug delivery of macromolecules across the blood-brain barrier. Expert Opin Drug Deliv. 2020;17:23–32.
Wang J, Tang W, Yang M, Yin Y, Li H, Hu F, Tang L, Ma X, Zhang Y, Wang Y. Inflammatory tumor microenvironment responsive neutrophil exosomes-based drug delivery system for targeted glioma therapy. Biomaterials. 2021;273: 120784.
Mingzhao Z. Beyond the traditional route of administration. Foreign Sci Technol Trends. 2001;12:8–9.
Mc Gillicuddy A, Crean AM, Sahm LJ. Older adults with difficulty swallowing oral medicines: a systematic review of the literature. Eur J Clin Pharmacol. 2016;72:141–151.
Kaur G, Arora M, Ravi Kumar MNV. Oral drug delivery technologies: a decade of developments. J Pharmacol Exp Ther. 2019;370:529–43.
McConville JT. Current developments in oral drug administration. Drug Dev Ind Pharm. 2017;43:699–676.
Öztürk AA, Arpagaus C. Nano Spray-Dried Drugs for Oral Administration: A Review. Assay Drug Dev Technol. 2021;19:412–441.
Nielsen LH, Keller SS, Boisen A. Microfabricated devices for oral drug delivery. Lab Chip. 2018;18:2348–2358.
Pennington CA, Park JM. Sublingual tacrolimus as an alternative to oral administration for solid organ transplant recipients. Am J Health Syst Pharm. 2015;72:277–284.
Goswami T, Jasti B, Li X. Sublingual drug delivery. Crit Rev Ther Drug Carrier Syst. 2008; 25:449–484.
Usach I, Martinez R, Festini T, Peris JE. Subcutaneous Injection of Drugs: Literature Review of Factors Influencing Pain Sensation at the Injection Site. Adv Ther. 2019; 36:2986–2996.
Logomasini MA, Stout RR, Marcinkoski R. Jet injection devices for the needle-free administration of compounds, vaccines, and other agents. Int J Pharm Compd. 2013; 17:270–280.
Frid AH, Hirsch LJ, Menchior AR, Morel DR, Strauss KW. Worldwide Injection Technique Questionnaire Study: Injecting Complications and the Role of the Professional. Mayo Clin Proc. 2016;91:1224–1230.
Van Hoogdalem EJ, de Boer AG, Breimer DD. Pharmacokinetics of rectal drug administration, Part II. Clinical applications of peripherally acting drugs, and conclusions. Clin Pharmacokinet. 1991; 21:110–128.
Lowry M. Rectal drug administration in adults: how, when, why. Nurs Times. 2016; 112:12–14.
Yang Chunlan HQ, Ye Yong. Research progress of nano-drug delivery system of traditional Chinese medicine in the treatment of brain diseases. Chinese Journal of Traditional Chinese Medicine. 2021; 39:38–43.
Vargason AM, Anselmo AC, Mitragotri S. The evolution of commercial drug delivery technologies. Nat Biomed Eng. 2021;5:951–967.
Bae YH, Park K. Advanced drug delivery 2020 and beyond: Perspectives on the future. Adv Drug Deliv Rev. 2020; 158:4–16.
Martinho N, Damgé C, Reis CP. Recent advances in drug delivery systems. Journal of biomaterials and nanobiotechnology. 2011;2:510–516.
Jain K K. Drug delivery systems-an overview. Drug delivery systems. 2008;20:1–50.
Zhuang W, Liu S-L, ** S-Y, Feng Y-N, Wang K, Abduwali T, Liu P, Zhou X-J, Zhang L, Dong X-Z. Traditional Chinese medicine decoctions and Chinese patent medicines for the treatment of depression: Efficacies and mechanisms. Journal of Ethnopharmacology. 2023;45:116272–116281.
Li Ruyue DG, Yang **nyi. Study on pharmacodynamics and pharmacokinetics of Hypericum perforatum combined with sertraline in depression model rats. Jiangsu Traditional Chinese Medicine. 2022;54:69–73.
Cao Shanshan SY, Zhang Ruihua. Research progress of antidepressant Bupleurum prescription and saikosaponins. Journal of Liaoning University of Traditional Chinese Medicine.2023;25(09):197–202.
Shen Shi W GX, Song Hongru. Regulatory effect and mechanism of magnesium baicalin on depression-like behavior and neuroinflammation induced by lipopolysaccharide in rats. China Journal of Pharmacy. 2023;58:338–346.
Zhao Zhiyu WW, Guo Hongzhu. Effect of liquiritin on weight and behavior of depression model rats. chinese mental health journal. 2006;12:787–790.
Zou Yuchi CJ, Huang Wenting. Effects of curcumin analogue L6H3 on monoamine neurotransmitter metabolites in striatum of Parkinson's disease rats. Journal of Wenzhou Medical University. 2019;49:625–629.
Zhang T-T, Jiang J-G. Active ingredients of traditional Chinese medicine in the treatment of diabetes and diabetic complications. Expert opinion on investigational drugs. 2012;21:1625–1642.
Liu X, Shi D, Zhou S, Liu H, Liu H, Yao X. Molecular dynamics simulations and novel drug discovery. Expert opinion on drug discovery. 2018;13:23–37
Huwyler J, Wu D, Pardridge WM. Brain drug delivery of small molecules using immunoliposomes. Proceedings of the National Academy of Sciences. 1996; 93:14164–14169.
Wang A-A, Li L, Li Y, Miao L, Pan Y-H, Liu J-X. Research progress on Chinese medicinal material-derived active polypeptides against ischemic cardiovascular and cerebrovascular diseases. China Journal of Chinese Materia Medica. 2021;46:5576–5584.
He Ying FF, Yan Hongli. Momordica charantia MAP30 promotes autophagy and apoptosis of multiple myeloma cells through AKT/mTOR pathway. chinese journal of cancer biotherapy. 2019; 26:299–305.
Shi Zhongkai HX, You Yuhong. Experimental study on anti-tumor activity of ethanol extract from roots of Linqian on S-180 tumor-bearing mice. journal of Chengdu University of Traditional Chinese Medicine. 2011;34:41–43.
Baolan S. Research progress of anti-liver injury traditional Chinese medicine and its mechanism of action. Everybody's Health (Academic Edition). 2014, 8:49–50.
Wang Baolong ZY, Jiang Yang. Immunological mechanism of trichosanthin inhibiting T cell proliferation. Chinese Journal of Microbiology and Immunology. 2015;12:68–72.
Alam MI, Beg S, Samad A, Baboota S, Kohli K, Ali J, Ahuja A, Akbar M. Strategy for effective brain drug delivery. European journal of pharmaceutical sciences. 2010; 40:385–403.
Ma G. Microencapsulation of protein drugs for drug delivery. strategy, preparation, and applications. Journal of Controlled Release. 2014;193:324–340.
Li C, Wang J, Wang Y, Gao H, Wei G, Huang Y, Yu H, Gan Y, Wang Y, Mei L. Recent progress in drug delivery. Acta pharmaceutica sinica B. 2019;9:1145–1162
Liechty WB, Kryscio DR, Slaughter BV, Peppas NA. Polymers for drug delivery systems. Annual review of chemical and biomolecular engineering. 2010;1:149–152.
Manzari MT, Shamay Y, Kiguchi H, Rosen N, Scaltriti M, Heller DA. Targeted drug delivery strategies for precision medicines. Nature Reviews Materials. 2021;6:351–370.
Cai SS, Li T, Akinade T, Zhu Y, Leong KW. Drug delivery carriers with therapeutic functions. Advanced Drug Delivery Reviews. 2021;176:13884–13891.
Purabisaha RK, Rawat SSN, Prakash A. A Review On Novel Drug Delivery System. 2021;14:56–67.
Tewabe A, Abate A, Tamrie M, Seyfu A, Abdela Siraj E. Targeted drug delivery—from magic bullet to nanomedicine: principles, challenges, and future perspectives. Journal of Multidisciplinary Healthcare. 2021;67:1711–1724.
Hakim LK, Yazdanian M, Alam M, Abbasi K, Tebyaniyan H, Tahmasebi E, Khayatan D, Seifalian A, Ranjbar R, Yazdanian A. Biocompatible and biomaterials application in drug delivery system in oral cavity. Evidence-based Complementary and Alternative Medicine. 2021;56:77–81.
Alqahtani MS, Kazi M, Alsenaidy MA, Ahmad MZ. Advances in oral drug delivery. Frontiers in pharmacology.2021;12:618411–618417.
Haywood A, Glass BD. Pharmaceutical excipients–where do we begin? Australian prescriber. 2011;21:32–34.
Am Ende MT. Chemical engineering in the pharmaceutical industry: Active pharmaceutical ingredients. John Wiley & Sons. 2019;24:18–21
Zompra AA, Galanis AS, Werbitzky O, Albericio F. Manufacturing peptides as active pharmaceutical ingredients. Future Med Chem.2009;1:361–377.
Park H, Otte A, Park K. Evolution of drug delivery systems: From 1950 to 2020 and beyond. Journal of Controlled Release.2022;342:53–65.
Yukun Z. Construction and pharmacodynamic evaluation of mesoporous silica nanocarriers loaded with Huanglian Jiedu Decoction co-modified by OX26/ApoE. Tian** University of Traditional Chinese Medicine. 2021;25:101–105
Yuanyuan Z. Study on percutaneous photothermal chemotherapy guided by dual-mode imaging of multifunctional SPIO nanocarriers for superficial tumors. China University of Science and Technology.2021;43:32–34
Tang **ang YS, zhouxiang dong. Research progress of nanostructured lipid carriers in lung targeted delivery system. China Pharmaceutical.2023;32:1–5.
Linxia J. Study on Intervention of Cytokine Storm in ALI by Curcumin Liposomes Targeted by M1 Macrophages. Bei**g University of Chinese Medicine.2021;45:34–36
Ying Z. Novel multifunctional liposome based on ginsenoside Rg3 and its application in targeted tumor therapy. Guangzhou University of Chinese Medicine. 2019;48:104–109
Zhou Ruiyi SY, Wu Yueming. Study on antibacterial function of polyurethane surface modified by β -polypeptide polymer with endothelialization promoting effect. Acta Macromolecular.2023;54:1055–1063.
Cui Yuqi LF, Zhang Linqian. Progress in bioanalysis methods and pharmacokinetics of polymer nano-pharmaceutical preparations. Journal of Pharmacy. 2023;58:844–851.
Gu Wei WC, Liu **aowei. Synthesis of water-soluble paliperidone prodrug and its transdermal study in vitro. Drug evaluation research. 2022; 45:2008–2016.
Yuanyuan L. Preparation of albumin-bound paclitaxel prodrug and evaluation of its antitumor activity in vitro and in vivo. Shandong University. 2022;34:46–47.
Zong-ru G. Clopidogrel, a biological prodrug fortunately discovered. Acta Pharmacy. 2022; 57:1537–1540
Jiang Yuanqi DY, Chen **peng. Research progress of targeted preparations of traditional Chinese medicine. Chinese Herbal Medicine. 2021; 52:1156–1164
Su Hui LC. Research progress of targeted preparation in the treatment of rheumatoid arthritis. Medical Journal. 2020; 39:1672–1676.
Fang Lin ZP, Zhang Qing. Research progress of targeted preparations of adriamycin. Zhongnan Pharmacy. 2018; 16:1263–1267
Chen Mengzhang LH. Research progress of therapeutic nucleic acid and viral vector vaccine for chronic hepatitis B. pharmaceutical biotechnology. 2023; 30:83–89
Chen Juan PL, Yang **aoyi. Analysis of global research and development situation of virus vector vaccine products. China Pharmaceutical. 2022; 31:24–29.
Barkat MA, Harshita, Rizwanullah M, Pottoo FH, Beg S, Akhter S, Ahmad FJ. Therapeutic Nanoemulsion: Concept to Delivery. Curr Pharm Des. 2020; 26:1145–1166.
Lu XY, Wu DC, Li ZJ, Chen GQ. Polymer nanoparticles. Prog Mol Biol Transl Sci. 2011; 104:299–323.
Elvira C, Gallardo A, Roman JS, Cifuentes A. Covalent polymer-drug conjugates. Molecules. 2005; 10:114–125.
Dang W, Colvin OM, Brem H, Saltzman WM. Covalent coupling of methotrexate to dextran enhances the penetration of cytotoxicity into a tissue-like matrix. Cancer Res. 1994; 54:1729–1735.
Guan Qingxia HX, Li Weinan.Research progress of liver-targeted nano-drug delivery system loaded with traditional Chinese medicine. China Pharmacy. 2015; 26:1002–1005
LI Hong,ZHUO Yunyun. Research progress on the preparation method and application of drug-loaded nanoparticles. Guangdong Chemical Industry.2013;40:86–71.
Duan **aoying JQ, Liu Lina. Preparation of Matrine Nanoparticles and Modified Products of Wheat Germ Lectin. Chinese Patent Medicine. 2017; 39:55–60.
Harwansh RK, Deshmukh R, Rahman MA. Nanoemulsion: Promising nanocarrier system for delivery of herbal bioactives. Journal of Drug Delivery Science and Technology. 2019; 51:224–233.
Zhang Yanfang GY, Wu Rina. Research progress of Chinese medicine extract nanoemulsion and its pharmacokinetics. China Journal of Chinese Medicine Information. 2020;27:141–144.
Kotta S, Aldawsari HM, Badr-Eldin SM, Alhakamy NA, Md S. Coconut oil-based resveratrol nanoemulsion: Optimization using response surface methodology, stability assessment and pharmacokinetic evaluation. Food Chemistry. 2021; 357:129–131.
Mohamed S, Parayath NN, Taurin S, Greish K. Polymeric nano-micelles: versatile platform for targeted delivery in cancer. Ther Deliv. 2014; 5:1101–1121
Hwang D, Ramsey JD, Kabanov AV. Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. Adv Drug Deliv Rev. 2020; 156:80–118.
Gill KK, Kaddoumi A, Nazzal S. Mixed micelles of PEG(2000)-DSPE and vitamin-E TPGS for concurrent delivery of paclitaxel and parthenolide: enhanced chemosenstization and antitumor efficacy against non-small cell lung cancer (NSCLC) cell lines. Eur J Pharm Sci. 2012; 46:64–71.
Shah S, Dhawan V, Holm R, Nagarsenker MS, Perrie Y. Liposomes: Advancements and innovation in the manufacturing process. Adv Drug Deliv Rev. 2020;154-155:102–122.
Almeida B, Nag OK, Rogers KE, Delehanty JB. Recent Progress in Bioconjugation Strategies for Liposome-Mediated Drug Delivery. Molecules. 2020; 25:1–6.
Guimarães D, Cavaco-Paulo A, Nogueira E. Design of liposomes as drug delivery system for therapeutic applications. Int J Pharm 2021, 601:120571. 97.Yan Dekang ZX, Wang Yujia: Formulation optimization of mannose modified curcumin/ginsenoside Rb1 liposomes and evaluation of brain targeting in vitro. China Pharmacist.2022; 25:11–17.
Yan Dekang ZX, Wang Yujia. Formulation optimization of mannose modified curcumin/ginsenoside Rb1 liposomes and evaluation of brain targeting in vitro. China Pharmacist. 2022, 25:11–17.
Walther R, Rautio J, Zelikin AN. Prodrugs in medicinal chemistry and enzyme prodrug therapies. Adv Drug Deliv Rev. 2017; 118:65–77.
Kang T, Miao Z, Liu S, Ke B. Prodrug Strategies in the CNS Drugs: Small Modification Makes Big Improvements. Curr Top Med Chem. 2021; 21:2157–2169.
Chen KJ, Plaunt AJ, Leifer FG, Kang JY, Cipolla D. Recent advances in prodrug-based nanoparticle therapeutics. Eur J Pharm Biopharm. 2021; 165:219–243
Abet V, Filace F, Recio J, Alvarez-Builla J, Burgos C.Prodrug approach: An overview of recent cases. Eur J Med Chem. 2017; 127:810–827
Mehellou Y, Rattan HS, Balzarini J. The ProTide Prodrug Technology: From the Concept to the Clinic. J Med Chem. 2018; 61:2211–2226.
Jana S, Mandlekar S, Marathe P. Prodrug design to improve pharmacokinetic and drug delivery properties: challenges to the discovery scientists. Curr Med Chem. 2010; 17:3874–3908.
Bodor N, Kaminski JJ.Prodrugs and site-specific chemical delivery systems. In Annual Reports in Medicinal Chemistry. 1987;22:303–313.
Lanlan J. Design, synthesis and evaluation of prodrug of ligustrazine derivative A11 against ischemic stroke, and discovery of new lead compounds of selective butyrylcholinesterase inhibitors. Shandong University. 2020;67:71–78.
He F, Wen N, **ao D, Yan J, **ong H, Cai S, Liu Z, Liu Y.Aptamer-Based Targeted Drug Delivery Systems: Current Potential and Challenges. Curr Med Chem. 2020;27:2189–2219.
Liu P, Jiang C. Brain-targeting drug delivery systems. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2022; 14:1818–1920.
Shah V, Kochar P. Brain Cancer.Implication to Disease, Therapeutic Strategies and Tumor Targeted Drug Delivery Approaches. Recent Pat Anticancer Drug Discov. 2018; 13:70–85.
Morachis JM, Mahmoud EA, Almutairi A. Physical and chemical strategies for therapeutic delivery by using polymeric nanoparticles. Pharmacol Rev. 2012; 64:505–519.
Tian B, Hua S, Tian Y, Liu J.Chemical and physical chitosan hydrogels as prospective carriers for drug delivery: a review. J Mater Chem B. 2020; 8:10050–10064.
Haiyan H. Research Progress of Magnetic Targeting in Physicochemical Targeting Preparations. Guangzhou Chemical Industry. 2015; 43:26–28.
Polyak B, Friedman G. Magnetic targeting for site-specific drug delivery: applications and clinical potential. Expert Opin Drug Deliv. 2009; 6:53–70.
Bietenbeck M, Florian A, Faber C, Sechtem U, Yilmaz A. Remote magnetic targeting of iron oxide nanoparticles for cardiovascular diagnosis and therapeutic drug delivery: where are we now? Int J Nanomedicine. 2016; 11:3191–3203.
Yan Runmin LC, Zhao Ming. Experimental study on distribution of magnetic paclitaxel-ferroferric oxide-drug-loaded liposome complex particles in brain. biomedical engineering and clinical medicine. 2011; 15:103–106+188.
Peng N, Yu H, Yu W, Yang M, Chen H, Zou T, Deng K, Huang S, Liu Y. Sequential-targeting nanocarriers with pH-controlled charge reversal for enhanced mitochondria-located photodynamic-immunotherapy of cancer. Acta Biomater. 2020; 105:223–238.
Chen Conghui LM. Anti-tumor study of targeting and pH-sensitive lipoprotein-like nano-carriers carrying paclitaxel in vivo. China Journal of Traditional Chinese Medicine. 2019; 44:2072–2077.
Shirley JL, de Jong YP, Terhorst C, Herzog RW. Immune Responses to Viral Gene Therapy Vectors. Mol Ther. 2020; 28:709–722.
Anderson WF. Prospects for human gene therapy. Science. 1984; 226:401–409
Milone MC, O'Doherty U. Clinical use of lentiviral vectors. Leukemia. 2018; 32:1529–1541.
Jolly D. Viral vector systems for gene therapy. Cancer Gene Ther. 1994; 1:51–64
Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet. 2003; 4:346–358
Halperin SA, Ye L, MacKinnon-Cameron D, Smith B, Cahn PE, Ruiz-Palacios GM, Ikram A, Lanas F, Lourdes Guerrero M, Muñoz Navarro SR, et al. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. Lancet. 2022; 399:237–248.
Zhang YH, Wang Y, Yusufali AH, Ashby F, Zhang D, Yin ZF, Aslanidi GV, Srivastava A, Ling CQ, Ling C. Cytotoxic genes from traditional Chinese medicine inhibit tumor growth both in vitro and in vivo. J Integr Med. 2014; 12:483–494.
Raposo G, Stahl PD. Extracellular vesicles. a new communication paradigm? Nature Reviews Molecular Cell Biology. 2019; 20:509–510
Söllner T, Whiteheart SW, Brunner M, Erdjument-Bromage H, Geromanos S, Tempst P, Rothman JE. SNAP receptors implicated in vesicle targeting and fusion. Nature. 1993; 362:318–324.
Elsharkasy OM, Nordin JZ, Hagey DW, de Jong OG, Schiffelers RM, Andaloussi SE, Vader P. Extracellular vesicles as drug delivery systems: Why and how? Advanced drug delivery reviews. 2020; 159:332–343.
Zhao L, Hu C, Han F, Wang J, Chen J. Regenerative abilities of mesenchymal stem cells via acting as an ideal vehicle for subcellular component delivery in acute kidney injury. J Cell Mol Med. 2020; 24:4882–4891
De Castilla PEM, Tong L, Huang C, Sofias AM, Pastorin G, Chen X, Storm G, Schiffelers RM, Wang J-W. Extracellular vesicles as a drug delivery system: A systematic review of preclinical studies. Advanced drug delivery reviews. 2021; 175:113801–113823.
Zhu Q, Ling X, Yang Y, Zhang J, Li Q, Niu X, Hu G, Chen B, Li H, Wang Y, Deng Z. Embryonic Stem Cells-Derived Exosomes Endowed with Targeting Properties as Chemotherapeutics Delivery Vehicles for Glioblastoma Therapy. Adv Sci (Weinh). 2019; 6:1809–1899.
Villa F, Quarto R, Tasso R. Extracellular vesicles as natural, safe and efficient drug delivery systems. Pharmaceutics. 2019; 11:557–561.
Zou J, Shi M, Liu X, ** C, **ng X, Qiu L, Tan W. Aptamer-Functionalized Exosomes: Elucidating the Cellular Uptake Mechanism and the Potential for Cancer-Targeted Chemotherapy. Anal Chem. 2019; 91:2425–2430.
** X-M, **a S-J, Lu R. Drug loading techniques for exosome-based drug delivery systems. Die Pharmazie-An International Journal of Pharmaceutical Sciences. 2021; 76:61–67.
Ajazuddin, Saraf S. Applications of novel drug delivery system for herbal formulations. Fitoterapia. 2010; 81:680–689.
Song Sankong BY, Liang Jiandi. Application progress of parallel artificial membrane osmotic model in drug permeability screening of transdermal drug delivery system. China Pharmacy. 2023; 34:502–507.
** Yuanyuan ZX, Chen Jiangli. Research progress of new drug delivery system in transdermal drug delivery. Jilin Traditional Chinese Medicine. 2022; 42:1477–1480.
Xue Yaqi WZ, Liang Peiyi. Progress in molecular pharmaceutics of transdermal preparations of traditional Chinese medicine. Journal of Nan**g University of Traditional Chinese Medicine. 2022; 38:983–989.
Zhou Ziye GM, Chen Peng. meta-analysis of the effectiveness and safety of midazolam nasal administration in children's oral diagnosis and treatment. journal of clinical stomatology. 2023; 39:42–47.
Wang **g CR, Ge Yuansha. Study on the law of nasal administration in ancient Chinese medicine. Western Chinese Medicine. 2022; 35:113–117.
Li Juan LY, Liu Ying. Anti-epileptic effect of ginsenoside Rb_1 by nasal administration on pentylenetetrazol-ignited mice. chinese journal of experimental traditional medical formulae. 2022, 28:65–74.
Eng Yuhui HZ, Lin Honglin. Analysis of the curative effect of pevisone in the treatment of fungal otitis externa. china journal of endoscopy. 2022; 28:56–62.
Yang Hong ZJ, Ren Danni. Safety evaluation of volatile oil from Artemisia argyi by external auditory canal in guinea pigs. Journal of Yunnan College of Traditional Chinese Medicine. 2020; 43:11–15.
Thwala LN, Préat V, Csaba NS. Emerging delivery platforms for mucosal administration of biopharmaceuticals: a critical update on nasal, pulmonary and oral routes. Expert Opin Drug Deliv. 2017; 14:23–36
Naik A, Kalia YN, Guy RH. Transdermal drug delivery: overcoming the skin's barrier function. Pharm Sci Technol Today. 2000; 3:318–326.
Mavuso S, Marimuthu T, Choonara YE, Kumar P, du Toit LC, Pillay V. A review of polymeric colloidal nanogels in transdermal drug delivery. Curr Pharm Des. 2015; 21:2801–2813.
Lan Y, Wang J, Li H, Zhang Y, Chen Y, Zhao B, Wu Q. Effect of menthone and related compounds on skin permeation of drugs with different lipophilicity and molecular organization of stratum corneum lipids. Pharm Dev Technol. 2016; 21:389–398.
Balfour DJ, Fagerström KO. Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders. Pharmacol Ther. 1996; 72:51–81.
Rezvani AH, Levin ED. Cognitive effects of nicotine. Biol Psychiatry. 2001; 49:258–267.
Singh N, Pillay V, Choonara YE. Advances in the treatment of Parkinson's disease. Prog Neurobiol. 2007; 81:29–44.
Shen Chengying SB, Xu **hua. Preparation of Ganoderma lucidum triterpenoid nanosuspension gel and its transdermal study in vitro. Chinese Herbal Medicine. 2014; 45:2770–2775.
Siegel SJ, Winey KI, Gur RE, Lenox RH, Bilker WB, Ikeda D, Gandhi N, Zhang WX. Surgically implantable long-term antipsychotic delivery systems for the treatment of schizophrenia. Neuropsychopharmacology. 2002; 26:817–823.
Rabin C, Liang Y, Ehrlichman RS, Budhian A, Metzger KL, Majewski–Tiedeken C, Winey KI, Siegel SJ. In vitro and in vivo demonstration of risperidone implants in mice. Schizophr Res. 2008; 98:66–78.
Wang Z, **ong G, Tsang WC, Schätzlein AG, Uchegbu IF. Nose-to-Brain Delivery. J Pharmacol Exp Ther. 2019; 370:593–601.
Lobaina Mato Y. Nasal route for vaccine and drug delivery: Features and current opportunities. Int J Pharm. 2019; 572:118–123.
Kashyap K, Shukla R. Drug Delivery and Targeting to the Brain Through Nasal Route: Mechanisms, Applications and Challenges. Curr Drug Deliv. 2019; 16:887–901.
Dongyuan L. Theory of Qi Alternation in Five Organs. Bulletin of Traditional Chinese Medicine. 2016;15:40–46.
Hou H, Li Y, Xu Z, Yu Z, Peng B, Wang C, Liu W, Li W, Ye Z, Zhang G. Applications and research progress of Traditional Chinese medicine delivered via nasal administration. Biomed Pharmacother. 2023; 157:113–133.
Yang CX, Xu XH, Dong Y. Advances in the research on targeted preparations of traditional Chinese medicine and natural drugs. Chinese Journal of Traditional Medicine. 2003; 28:696–700.
Ju Aichun GS, Yang **npeng. Effects of nasal administration of salvianolic acid B on learning and memory ability and nerve regeneration in rats with cerebral ischemia injury. Chinese Herbal Medicine. 2017; 48:2481–2485.
Sun Ya** ZY, Bai Ning. Effect of short-term nasal administration of genistein on alleviating neuronal damage after cerebral infarction in rats. Chinese Journal of Coal Industry Medicine. 2018; 21:310–315.
Guo Q, Li P, Wang Z, Cheng Y, Wu H, Yang B, Du S, Lu Y. Brain distribution pharmacokinetics and integrated pharmacokinetics of Panax Notoginsenoside R1, Ginsenosides Rg1, Rb1, Re and Rd in rats after intranasal administration of Panax Notoginseng Saponins assessed by UPLC/MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2014;969:264–271.
Dong Y, Shi J-R. Biological research evaluating the Chinese medical theory of the association of the kidney with the ears. Zhong xi yi jie he xue bao= Journal of Chinese Integrative Medicine. 2012; 10:128–134.
Hou P-W, Hsu H-C, Lin Y-W, Tang N-Y, Cheng C-Y, Hsieh C-L. The history, mechanism, and clinical application of auricular therapy in traditional Chinese medicine. Evidence-Based Complementary and Alternative Medicine. 2015; 789:12–17.
Hang Y. Construction and evaluation of micro-robot drug delivery device that can continuously overcome the double physiological barrier of external ear/middle ear/inner ear. Guangdong Pharmaceutical University. 2020;234:47–56.
An **aogang CD. Research progress of nano-particle drug delivery system in inner ear targeted drug delivery. Chinese Journal of Otology. 2020; 18:409–413.
Jiang W-Y. Therapeutic wisdom in traditional Chinese medicine: a perspective from modern science. Trends in pharmacological sciences. 2005;26:558–563.
Liu H, Hao J, Li KS. Current strategies for drug delivery to the inner ear. Acta Pharmaceutica Sinica B. 2013; 3:86–96.
Qiu K, Mao M, Deng D, Jiang C, Li L, Zheng Y, Ren J, Zhao Y. Is postauricular injection a systemic or a topical route for inner ear drug delivery? Hearing Research. 2022; 422:108570–108587.
Lee S, Dondzillo A, Gubbels SP, Raphael Y. Practical aspects of inner ear gene delivery for research and clinical applications. Hearing research. 2020; 394:107–134.
gang C. construction of compound inner ear drug delivery system of traditional Chinese medicine and study on drug delivery mechanism. 2017;48:32–36
Pferschy-Wenzig E-M, Bauer R. The relevance of pharmacognosy in pharmacological research on herbal medicinal products. Epilepsy & behavior. 2015; 52:344–362.
**g**g W, Rongjuan G, Guo**g F, **%2CCY&author=Tang%2CL"> Google Scholar
Liu Y, Feng N. Nanocarriers for the delivery of active ingredients and fractions extracted from natural products used in traditional Chinese medicine (TCM). Advances in Colloid and Interface Science. 2015; 221:60–76.
Verma H, Prasad SB, Yashwant SH. Herbal drug delivery system: A modern era prospective. Int J Current Pharma Rev Res. 2013; 4:88–101.
Feixu J. Study on targeted therapy of triple negative breast cancer with ROS responsive up-conversion nano-drug delivery system. Zhejiang University. 2022;72:277–84.
Wang Yue HY, Zhu Dandan. Application of nano-drug delivery system based on polyamide dendrimer prodrug in the treatment of malignant tumor. Zhongnan Pharmacy. 2021; 19:1343–1352.
Liu Yuan ZX, Zhang Cheng. Effects of berberine hydrochloride-soy protein isolate sustained-release gel on the efficacy and intestinal flora of type 2 diabetic mice. China Hospital Pharmaceutical Journal. 2023;45:1–7.
Li Bonan NG, Sun Tiansong. Progress in research and application of exosomes on testicular microenvironment. Progress in biochemistry and biophysics. 2022; 49:2328–2341.
Jiang Jianbo SQ, Ding Fengfei. Extracellular ion microenvironment regulates sleep awakening. chinese journal of clinical pharmacology and therapeutics. 2021; 26:794–801.
Dement'eva OV, Naumova KA, Zhigletsova SK, Klykova MV, Somov AN, Dunaytsev IA, Senchikhin IN, Volkov VV, Rudoy VM. Drug-templated mesoporous silica nanocontainers with extra high payload and controlled release rate. Colloids Surf B Biointerfaces. 2020; 185:110577.
Davoodi P, Lee LY, Xu Q, Sunil V, Sun Y, Soh S, Wang CH. Drug delivery systems for programmed and on-demand release. Adv Drug Deliv Rev. 2018; 132:104–138.
Yang D, Lee JS, Choi CK, Lee HP, Cho SW, Ryu W. Microchannel system for rate-controlled, sequential, and pH-responsive drug delivery. Acta Biomater. 2018; 68:249–260.
Severino P, da Silva CF, Andrade LN, de Lima Oliveira D, Campos J, Souto EB. Alginate Nanoparticles for Drug Delivery and Targeting. Curr Pharm Des. 2019; 25:1312–1334.
Torchilin VP. Drug targeting. Eur J Pharm Sci. 2000; 2:81–91.
Jain K. Nanobiotechnology-based drug delivery to the central nervous system. Neurodegenerative Diseases. 2007; 4:287–291.
Ipar VS, Dsouza A, Devarajan PV. Enhancing Curcumin Oral Bioavailability Through Nanoformulations. Eur J Drug Metab Pharmacokinet .2019; 44:459–480.
Blasi P, Giovagnoli S, Schoubben A, Ricci M, Rossi C. Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev. 2007; 59:454–477.
Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010; 75:1–18.
Silva GA. Nanotechnology approaches to crossing the blood-brain barrier and drug delivery to the CNS. BMC neuroscience. 2008; 9:1–4.
Anselmo AC, Mitragotri S. Nanoparticles in the clinic: An update. Bioeng Transl Med. 2019; 4:10143–10154.
Havel H, Finch G, Strode P, Wolfgang M, Zale S, Bobe I, Youssoufian H, Peterson M, Liu M. Nanomedicines: From Bench to Bedside and Beyond. Aaps j .2016; 18:1373–1378.
Silva GA. Nanotechnology applications and approaches for neuroregeneration and drug delivery to the central nervous system. Annals of the New York Academy of Sciences. 2010; 1199:221–230.
Huo Liang PY, Liu **nyu. Research progress of intestinal flora on metabolism of effective components of traditional Chinese medicine. Chinese Journal of Traditional Chinese Medicine. 2022; 37:1605–1608.
Zhang Qi JY, Zheng Hua-chan, Zhao Chong-bo. Research progress on the interaction between metabolism of effective components of traditional Chinese medicine and intestinal flora. Northwest Pharmaceutical Journal. 2022; 37:186–188.
Yuting J. Research progress of traditional Chinese medicine in regulating intestinal flora changes of colorectal cancer. Clinical research of traditional Chinese medicine. 2021; 13:136–138.
Ke Qunhua PJ, Wang Shengyi. Research progress on traditional Chinese medicine and intestinal flora and its metabolism. journal of traditional chinese veterinary medicine. 2022; 41:35–40.
Huang L, Zheng J, Sun G, Yang H, Sun X, Yao X, Lin A, Liu H. 5–Aminosalicylic acid ameliorates dextran sulfate sodium-induced colitis in mice by modulating gut microbiota and bile acid metabolism. Cell Mol Life Sci. 2022; 79:460–467.
Bi Huichang YM. Intestinal flora and drug metabolism. Pharmaceutical Progress. 2020; 44:81–82.
Jiang H, Ling Z, Zhang Y, Mao H, Ma Z, Yin Y, Wang W, Tang W, Tan Z, Shi J, et al: Altered fecal microbiota composition in patients with major depressive disorder. Brain Behav Immun. 2015; 48:186–194.
ZHANG Z-w, ZHAO Z-x, WANG Y, JIANG J-d. Research progress on the interaction of neuropsychiatric drugs with the gut microbiota. Acta Pharmaceutica Sinica. 2021;65:643–653.
Xu Yan LD, Ning Tingbo. Effects of Poria cocos on behavior and fecal flora in rats with mild and chronic unpredictable stress. China Pharmacovigilance. 2021; 18:748–752.
Cai Saibo ZH, **n **n. Effect of taking Bupleurum chinense DC. on intestinal flora diversity in depressed mice. China Journal of Traditional Chinese Medicine. 2021; 46:4222–4229.
Song Ruiwen ZL, Wang Shenjun. Analysis of the effect of Jiawei Wendan Decoction on intestinal flora of depression model rats based on 16S rDNA high-throughput sequencing technique. journal of traditional chinese medicine. 2021; 48:1–4+221.
Ji Xuyan HZ, Li Tao. Effect of Shunao Jieyu decoction on intestinal flora in patients with post-stroke depression. chinese journal of experimental traditional medical formulae. 2022;28:107–113.
Hou S, Gao Y-E, Ma X, Lu Y, Li X, Cheng J, Wu Y, Xue P, Kang Y, Guo M. Tumor microenvironment responsive biomimetic copper peroxide nanoreactors for drug delivery and enhanced chemodynamic therapy. Chemical Engineering Journal. 2021; 416:129–137.
David A. Peptide ligand-modified nanomedicines for targeting cells at the tumor microenvironment. Advanced drug delivery reviews. 2017; 119:120–142.
Zhang Zhigang FX, Lian Lulu. Research progress on regulating the permeability of blood-brain barrier by aromatic resuscitation drugs. 2022; 15:1510–1516.
Liu Chao LJ, Liu Shuwen. Study on the mechanism of regulating blood-brain barrier by aromatic resuscitation drugs and the treatment of encephalopathy. journal of changchun university of traditional chinese medicine. 2016; 32:874–877.
Cai Wei** CY, Tang Lichao. Effects of sodium aescinate on RhoA/ROCK pathway and blood-brain barrier permeability in rats with bacterial meningitis. China Journal of Microecology. 2022; 34:644–650.
Zhang Kai WK, Xu Y, Xu J, Xu S, Dai K, Qian J, Yang Q. Development of Hawthorn leaf total flavonoids extended-release capsules based on solid dispersion technology and study on the release mechanism of dru. Mod Chin Appl Pharm. 2017;34:378–384.
Bang YU, Huang C, Liu M, Zhang H. Systematic evaluation of traditional Chinese medicine nebulized inhalation method combined with conventional western medicine treatment for acute exacerbation of chronic obstructive pulmonary disease. Chin Med Emerg. 2023;32:941–946.
Baoolin L. A phase I clinical trial of clinical safety, tolerability, and pharmacokinetics of injectable and haptoglobin liposomes (HK) for the treatment of patients with advanced malignant solid tum. China Drug Clinical Trial Registration and Information Publication Platform. 2017; http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml. Accessed 21 Sept 2023.1–4.
Yu Z, Wang D, Qi Y, Liu J, Zhou T, Rao W, Hu K. Autologous-cancer-cryoablation-mediated nanovaccine augments systematic immunotherapy. Mater Horiz. 2023;10:1661–1677.
Lisa Liu GZ, Wang S, Su Z, Yu B, Ma T, Bai Z. Study on the effect of Chinese medicine acupoint application on infrared thermography and clinical efficacy and evaluation of traditional Chinese medicine in middle-aged and elderly patients with thoracic paralytic heartache. Liaoning J Chin Med. 2021;48:198–201.
Tingting D. Clinical study on the treatment of chloasma with soluble microneedle patches of "Yu Yan San". Shandong Univ Chin Med. 2022;43:12–15.
WANG Feifan,SONG Yunjia,WU Wenmeng et al. Analysis of the preparation and early drug release of epimedium glycoside/TiO2 nanotube composite coating on pure titanium surface. Chinese Tissue Engineering Research.2016;20(43):6416–6423.
Ying L. Tolerability and pharmacokinetic clinical trial study of single, multiple dose groups, randomized, double-blind, placebo-controlled, sustained-release microspheres of Staphylococcus aureus for Injection. China Drug Clinical Trial Registration and Information Publication Platform. 2014; http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml. Accessed 21 Sept 2023, 1–5.
Huaqing W. A phase I study to assess the tolerance and pharmacokinetics of ursolic acid liposomes. Chinese Clinical Trial Registry. 2015; https://www.chictr.org.cn/showproj.html?proj=132682. Accessed 21 Sept 2023,1–6.
Jianchun D. Real world study to evaluate paclitaxel liposome/carboplatin combined with PD-1 monoclonal antibody in the first-line treatment of advanced lung squamous cell carcinoma. Chinese Clinical Trial Registry. 2022; https://www.chictr.org.cn/showproj.html?proj=132682. Accessed 21 Sept 2023,1–4.
Su Y. A phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetic profile of injectable paclitaxel polymeric micelles in Chinese patients with advanced malignant solid tumors. China Drug Clinical Trial Registration and Information Publication Platform. 2021;http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml. Accessed 21 Sept 2023,1–5.
Acknowledgements
We would like to thank Professor Zhe Zhang for his critical review and helpful suggestions for this manuscript.
Funding
This study was granted by The **an City University Institute Innovation Team Project (grant number 2020GXRC012), special fund for high-level talent cultivation project of traditional Chinese medicine in Shandong Province (2023-143), Shanghai Science and Technology Development Foundation (2023-761027), Shandong Province Universities' Development Plan for Youth Innovation Teams (2019-9-202), and National Nature Science Foundation of China (81903948).
Author information
Authors and Affiliations
Contributions
SY: conceptualization, data curation, writing—original draft, visualization, investigation. TMa: Visualization, investigation. YNZ: supervision, funding acquisition. NW: visualization, investigation. ZQB: writing—review and editing, supervision. KMa: writing—review and editing, supervision, funding acquisition. All authors have read and approved the final version manuscript.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
Not applicable.
Consent for publication
All authors have approved the manuscript and agree with its submission.
Competing interests
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Yuan, S., Ma, T., Zhang, YN. et al. Novel drug delivery strategies for antidepressant active ingredients from natural medicinal plants: the state of the art. J Nanobiotechnol 21, 391 (2023). https://doi.org/10.1186/s12951-023-02159-9
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s12951-023-02159-9